"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 2 | 3 |
| 1996 | 2 | 3 | 5 |
| 1997 | 3 | 5 | 8 |
| 1998 | 9 | 5 | 14 |
| 1999 | 1 | 1 | 2 |
| 2000 | 5 | 3 | 8 |
| 2001 | 8 | 3 | 11 |
| 2002 | 12 | 6 | 18 |
| 2003 | 3 | 10 | 13 |
| 2004 | 9 | 9 | 18 |
| 2005 | 10 | 7 | 17 |
| 2006 | 6 | 14 | 20 |
| 2007 | 9 | 9 | 18 |
| 2008 | 8 | 21 | 29 |
| 2009 | 9 | 7 | 16 |
| 2010 | 13 | 8 | 21 |
| 2011 | 2 | 2 | 4 |
| 2012 | 6 | 8 | 14 |
| 2013 | 8 | 9 | 17 |
| 2014 | 14 | 10 | 24 |
| 2015 | 10 | 13 | 23 |
| 2016 | 13 | 5 | 18 |
| 2017 | 19 | 10 | 29 |
| 2018 | 10 | 12 | 22 |
| 2019 | 6 | 10 | 16 |
| 2020 | 12 | 10 | 22 |
| 2021 | 10 | 11 | 21 |
| 2022 | 2 | 9 | 11 |
| 2023 | 1 | 9 | 10 |
| 2024 | 2 | 7 | 9 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Association Between Early Immunosuppression Center Variability and One-Year Outcomes After Pediatric Liver Transplant. Pediatr Transplant. 2025 Feb; 29(1):e70018.
-
Budesonide, Added to PTCy-Based Regimen, for Prevention of Acute GI GVHD After Allogeneic Stem Cell Transplantation. Am J Hematol. 2025 Mar; 100(3):383-392.
-
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703. J Clin Oncol. 2025 Mar 10; 43(8):912-918.
-
Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. Clin Pharmacol Ther. 2025 Feb; 117(2):561-569.
-
Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology. Kidney Int. 2025 Jan; 107(1):21-32.
-
Systemic Therapy for Atopic Dermatitis in Children and Adolescents: A US Expert Consensus. Dermatology. 2024; 240(5-6):897-909.
-
Graft Versus Host Disease Prophylaxis in Matched Donor Stem Cell Transplantation: Post-transplantation Cyclophosphamide Combinations Versus Methotrexate/Tacrolimus. Transplant Proc. 2024 Sep; 56(7):1671-1677.
-
Study Protocol: Predicting the Quality of Response to Specific Treatments (PQRST) in Chronic Graft-versus-Host Disease. Contemp Clin Trials. 2024 Oct; 145:107637.
-
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors. J Clin Oncol. 2024 Oct; 42(28):3277-3286.
-
Chagas disease in the immunocompromised host. Curr Opin Infect Dis. 2024 Oct 01; 37(5):333-341.